Asian Journal of Medical Principles and Clinical Practice

Current Issue on Omicron COVID-19 Variants

Joel Burabari Konne *

School of Public Health, University of Port Harcourt, Rivers State, Nigeria.

Rhoda Nwalozie

Department of Medical Laboratory Science, Rivers State University, Port Harcourt, Nigeria.

Anthony N. Paago

College of Medicine, University of Ibadan, Oyo State, Nigeria.

Clement Ugochukwu Nyenke

Department of Medical Laboratory Science, Rivers State University, Port Harcourt, Nigeria.

*Author to whom correspondence should be addressed.

---

Abstract

Coronavirus Disease 2019 (COVID-19) according to the Nigeria Center for Disease Prevention and Control (NCDC) is a disease contracted from animals (zoonotic disease). Severe acute respiratory syndrome coronavirus (SARS COV-2) is the virus responsible for COVID-19. COVID-19 symptoms may develop within 14 days after infection with the virus and includes fever, headache, cough, difficulties with breathing, loss of smell and taste, and tiredness. In Africa, a new strain of COVID-19 was identified on the 24^th of November, 2021 in South Africa and tagged B.1.1.529, it was reported to the World Health Organization (WHO), which later named it Omicron. In December, 2021, the first cases of the Omicron variant were confirmed in Nigeria and has recorded up 45 cases by 20^th of the same month. It was reported that this three cases were identified in persons who arrived from South Africa the previous week. The Omicron variant is the dominant, and fast spreading variant of SARS Cov-2 across the world, and seven lineages of the variant has been identified so far since the naming of the strain and they include the Omicron B.1.1.529, BA.1, BA.1.1, BA.2, BA.3, BA.4 and BA.5 lineages. Laboratory methods for the diagnosis of Omicron sub-variants is the same as those for the general testing of COVID-19 which includes polymerase chain reaction, rapid tests, and additional tests to distinguish between the sub-variants. Patients with the earlier strains of severe COVID-19 are known to respond well to corticosteroids like dexamethasone and IL6 receptor blockers like tocilizumab (Actemra). All preventive measures observed for general SARS-CoV-2 prevention are applicable for Omicron variants prevention and they include vaccination, staying at home, donning a mask in public, avoidance of congested places, keeping social distancing, ventilating indoor spaces, controlling potential exposure durations, washing hands frequently and for at least 20 seconds, practicing good hygiene, and avoiding touching the eyes, nose, or mouth with unwashed hands are all preventative measures to lessen the likelihood of Omicron variant infection. All the measures employed in the prevention of COVID-19 outbreak proved to be effective against the Omicron variant also. As efforts continue towards containing the spread and minimizing the emergence of more variants, it becomes necessary to update the public on the current happening regarding the Omicron variant.

Keywords: SARS-CoV-2, omicron, variant, coronavirus, challenges

---

---

---

References

Nigeria Center for Disease Prevention and Control (NCDC) (2022). Frequently Asked Questions (FAQs).

Available:https://covid19.ncdc.gov.ng/faq/ Accessed September 21, 2022

World Health Organization (WHO) (2022). Coronavirus Disease (COVID-19).

Available:https://www.who.int/health-topics/coronavirus#tab=tab_1 Retrieved September 21, 2022

Dërmaku-Sopjani M, Sopjani M. Molecular characterization of SARS-CoV-2. Curr Mol Med. 221(7):589-595.

DOI: 10.2174/1566524020999201203213037

Oran DP, Topol EJ. "The proportion of SARS-CoV-2 infections that are asymptomatic: A systematic review". Annals of Internal Medicine. 2021;174(5): M20-6976.

DOI:10.7326/M20-6976

Islam MA. "Prevalence and characteristics of fever in adult and paediatric patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis of 17515 patients". PLOS ONE. 2021;16(4):e0249788. Bibcode: PLoSO.. 1649788I.

DOI:10.1371/journal.pone.0249788

Islam MA. "Prevalence of headache in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis of 14,275 patients". Frontiers in Neurology. 2020;11:562634.

DOI:10.3389/fneur.2020.562634

Saniasiaya J, Islam MA. "Prevalence of olfactory dysfunction in coronavirus disease 2019 (COVID-19): A meta-analysis of 27,492 patients". The Laryngoscope. 2021;131(4):865–878.

DOI:10.1002/lary.29286.

Saniasiaya J, Islam MA. "Prevalence and characteristics of taste disorders in cases of COVID-19: A meta-analysis of 29,349 patients". Otolaryngology–Head and Neck Surgery. 2020;165(1):33–42.

DOI:10.1177/0194599820981018.

Agyeman AA, Chin KL, Landersdorfer CB, Liew D, Ofori-Asenso R. "Smell and taste dysfunction in patients with COVID-19: A systematic review and meta-analysis". Mayo Clin. Proc. 2020;95(8):1621–1631.

DOI:10.1016/j.mayocp.

Gandhi RT, Lynch JB, Del Rio C. "Mild or moderate Covid-19". The New England Journal of Medicine. 2020;383(18):1757–1766.

DOI:10.1056/NEJMcp2009249

Byrne AW, McEvoy D, Collins AB, Hunt K, Casey M, Barber A, Butler F, Griffin J, Lane EA, McAloon C, O'Brien K. "Inferred duration of infectious period of SARS-CoV-2: rapid scoping review and analysis of available evidence for asymptomatic and symptomatic COVID-19 cases". BMJ Open. 2020;10(8):e039856.

DOI:10.1136/bmjopen-2020-039856

Grant MC, Geoghegan L, Arbyn M, Mohammed Z, McGuinness L, Clarke EL, Wade, RG. "The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): A systematic review and meta-analysis of 148 studies from 9 countries". PLOS ONE. 2020;15(6):e0234765. Bibcode:2020PLoSO..1534765G.

DOI:10.1371/journal.pone.0234765.

Centers for Disease Control and Prevention (CDC). SARS-CoV-2 variant classifications and definitions; 2022.

Available:https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifications.html Access on September 22, 2022

WHO2. Tracking SARS Cov-2 Variants; 2022.

Available:https://www.who.int/activities/tracking-SARS-CoV-2-variants Access on September 22, 2022

Musa SS, Gyeltshen D, Manirambona E, Ayuba D, Lucero-Prisno DE. The new COVID-19 omicron variant: Africa must watch its spread! Clin Epidemiol Glob Health. 2022;13:100961.

DOI: 10.1016/j.cegh.2022.100961

WHO3. Africa steps up Omicron variant detection as COVID-19 cases rise in Southern Africa; 2021.

Available:https://www.afro.who.int/news/africa-steps-omicron-variant-detection-covid-19-cases-rise-southern-africa Access on September 23, 2022

Anadulo Agency. Nigeria confirms 1st cases of omicron-variant; 2021.

Available:https://www.aa.com.tr/en/africa/nigeria-confirms-1st-cases-of-omicron-variant/2435520 Access on September 23, 2022.

The Cable. WHO: Omicron currently the dominant COVID variant in Nigeria; 2022.

Available:https://www.thecable.ng/who-omicron-currently-the-dominant-covid-variant-in-nigeria Access on September 23, 2022

Del Rio C, Omer SB, Malani PN. Winter of omicron-the evolving COVID-19 pandemic. JAMA. 2022;327(4):319-320.

DOI: 10.1001/jama.2021.24315 PMID: 34935863.

Quarleri J, Galvan V, Delpino MV. "Omicron variant of the SARS-CoV-2: a quest to define the consequences of its high mutational load". GeroScience. 2022;44(1):53–56.

DOI:10.1007/s11357-021-00500-4.

Gowrisankar A, Priyanka TM, Banerjee S. "Omicron: A mysterious variant of concern". European Physical Journal Plus. 2022;137(1):100. Bibcode:2022EPJP..137..100G.

DOI:10.1140/epjp/s13360-021-02321-y.

Vitiello A, Ferrara F, Auti AM, Di Domenico M, Boccellino M. "Advances in the omicron variant development". Journal of Internal Medicine. 2022;292 (1): 81–90.

DOI:10.1111/joim.13478.

Zhu N, Zhang D, Wang W, Li X, Yang B, et al. China novel coronavirus investigating and research team. A novel coronavirus from patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-733.

DOI: 10.1056/NEJMoa2001017

Wu CR, Yin WC, Jiang Y, Xu HE. Structure genomics of SARS-CoV-2 and its omicron variant: drug design templates for COVID-19. Acta Pharmacol Sin. 2022:1–13.

DOI: 10.1038/s41401-021-00851-w

Mohamadian M, Chiti H, Shoghli A, Biglari S, Parsamanesh N, Esmaeilzadeh A. COVID-19: Virology, biology and novel laboratory diagnosis. J Gene Med. 2021 23(2):e3303.

DOI: 10.1002/jgm.3303.

Trus I, Udenze D, Berube N, Wheler C, et al. CpG-recoding in zika virus genome causes host-age-dependent attenuation of infection with protection against lethal heterologous challenge in mice. Front Immunol. 2020;24;10:3077.

DOI: 10.3389/fimmu.2019.03077.

Cevik M, Bamford CGG, Ho A. COVID-19 pandemic-a focused review for clinicians. Clin Microbiol Infect. 202026(7):842-847.

DOI: 10.1016/j.cmi.2020.04.023

Monteil V, Kwon H, Prado P, Hagelkrüys A, Wimmer RA, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020181(4):905-913.e7.

DOI: 10.1016/j.cell.2020.04.004

Weiss SR, Leibowitz, JL. Coronavirus pathogenesis. Adv Virus Res. 2011;81:85-164.

DOI: 10.1016/B978-0-12-385885-6.00009-2

Kannan S, Shaik S, Ali P, Sheeza A. Evolving biothreat of variant SARS-CoV-2 - molecular properties, virulence and epidemiology. Eur Rev Med Pharmacol Sci. 2021;25(12):4405-4412.

DOI: 10.26355/eurrev_202106_26151

Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and Is blocked by a clinically proven protease inhibitor. Cell. 2020181(2):271-280.e8.

DOI: 10.1016/j.cell.2020.02.052.

Diana K. Omicron’s molecular structure could help explain its global takeover. Nature. 2022;602:373-374.

Available:https://doi.org/10.1038/d41586-022-00292-3

Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;181(2):281-292.e6.

DOI: 10.1016/j.cell.2020.02.058

Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, et al. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020;581(7807):221-224.

DOI: 10.1038/s41586-020-2179-y

WHO (2021). Update on Omicron.

https://www.who.int/news/item/28-11-2021-update-on-omicron Access on September 30, 2022

Scribner H. "Doctor reveals new nightly omicron variant symptom". Deseret News. 2021. Access on September 30, 2022.

Quann J. "Luke O'Neill: Night sweats now a sign of BA.5 COVID variant". Newstalk. 2022. Access on September 30, 2022.

Slater J. "Is a change to your taste or smell a sign of omicron?". Metro; 2022.

Access on September 30, 2022.

CDC COVID-19 Response Team. "SARS-CoV-2 B.1.1.529 (Omicron) Variant - United States, December 1-8, 2021". MMWR. Morbidity and Mortality Weekly Report. Center for Disease Control. 2021;70(50):1731–1734.

DOI:10.15585/mmwr.mm7050e1

The Guardian. Omicron's cold-like symptoms mean UK guidance 'needs urgent update'; 2021

https://www.theguardian.com/world/2021/dec/24/omicron-covid-symptoms-uk-guidance-zoe-study Access on September 30, 2022

Berger M. "South Africa, which found the omicron variant first, leads Africa in coronavirus sequencing". Washington Post; 2021.

https://www.washingtonpost.com/world/2021/11/28/coronavirus-genetic-sequence-south-africa-variant-omicron/ Accessed September 30, 2022

Geddes L. "How big is the risk of omicron in the UK and how do we know?". The Guardian; 2021.

Available:https://www.theguardian.com/world/2021/dec/14/how-big-is-the-risk-of-omicron-in-the-uk-and-how-do-we-know Retrieved September 30, 2022

Folkehelseinstituttet. "Statistikk over meldte tilfeller av virusvarianten omikron". (In Norwegian); 2021.

Available:https://www.fhi.no/sv/smittsomme-sykdommer/corona/meldte-tilfeller-av-ny-virusvariant/ Access on September 30, 2021.

Tahmasebi S, Khosh E, Esmaeilzadeh A. The outlook for diagnostic purposes of the 2019-novel coronavirus disease. J Cell Physiol. 2020;235(12):9211-9229.

DOI: 10.1002/jcp.29804

Ettaboina SK, Nakkala K, Laddha K. A mini review on SARS‐COVID‐19‐2 omicron variant (B. 1.1. 529). Sci Med J. 2021;3(4):399‐406.

DOI: 10.28991/SciMedJ-2021-0304-10

Cathcart AL, Havenar-Daughton C, Lempp FA, Ma D, Schmid M, Agostini ML, et al. "The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent In vitro and In vivo activity against SARS-CoV-2". Bio Rxiv; 2021.

DOI: 10.1101/2021.03.09.434607

McCallum M, Czudnochowski N, Rosen LE, Zepeda SK, Bowen JE, Dillen JR, et al. "Structural basis of SARS-CoV-2 omicron immune evasion and receptor engagement". Bio Rxiv; 2021.

DOI:10.1101/2021.12.28.474380.

Cao Y, Wang J, Jian F, Xiao T, Song W, Yisimayi A, et al. "Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies". Nature. 2022; 602(7898):657–663.

DOI:10.1038/d41586-021-03796-6

Cameroni E, Saliba C, Bowen JE, Rosen LE, Culap K, Pinto D, et al. "Broadly neutralizing antibodies overcome SARS-CoV-2 omicron antigenic shift". Bio Rxiv; 2021.

DOI:10.1038/d41586-021-03825-4.

U.S Department for Health and Human Service. Distribution of sotrovimab paused to certain states; 2022.

Available:https://aspr.hhs.gov/COVID-19/Therapeutics/updates/Pages/important-update-25March2022.aspx Accessed September 30, 2022

CDC. Scientific Brief: SARS-CoV-2 Transmission; 2021.

Available:https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/sars-cov-2-transmission.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fscience%2Fscience-briefs%2Fscientific-brief-sars-cov-2.html Accessed October 1, 2022

He X, Hong W, Pan X, Lu G, Wei X. SARS-CoV-2 Omicron variant: Characteristics and prevention. Med Comm (2020). 2021;2(4):838-845.

DOI: 10.1002/mco2.110.

Pulliam JRC, Van Schalkwyk C, Govender N, et al. Increased risk of SARS‐CoV‐2 reinfection associated with emergence of the omicron variant in South Africa. Medrxiv; 2021.

DOI: 10.1101/2021.11.11.21266068.

Cele S, Jackson L, Khan K, et al. SARS‐CoV‐2 omicron has extensive but incomplete escape of pfizer BNT162b2 elicited neutralization and requires ACE2 for infection. Medrxiv; 2021.

DOI: 10.1101/2021.12.08.21267417

Choi A, Koch M, Wu K, Chu L, Ma L, Hill A, et al. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: An interim analysis. Nat Med. 2021;27(11):2025-2031.

DOI: 10.1038/s41591-021-01527-y

WHO How Nigeria is tackling COVID-19 variants; 2021.

Available:https://www.afro.who.int/news/how-nigeria-tackling-covid-19-variants Access on October 1, 2022.